Literature DB >> 3243323

Influence of obesity on sulfonamide disposition in Zucker rats.

S Kaul1, W A Ritschel.   

Abstract

The genetically obese Zucker rat was used as a model of obesity and compared to its lean littermate to assess and quantify obesity-altered changes in the in vivo disposition of six sulfonamides. Body composition determination indicated that the obese rats were twice the weight of lean rats and a distinct trend towards an increase in fat free mass and total body water was observed. The sulfonamide blood concentration was measured by colorimetry after a 7 mg/kg intravenous dose. All sulfonamides exhibited a biexponential decline of blood concentration with time. The volume of distribution and clearance of sulfanilamide in lean and obese rats were similar resulting in similar elimination half-lives. A decrease in clearance coupled with a trend towards an increase in volume of distribution prolonged the elimination half-life of sulfadiazine in obese rats. For sulfapyridine, sulfamerazine, sulfisomidine and sulfisoxazole, increases in the volumes of distribution and clearances resulted in similar elimination half-lives in lean and obese rats. The free fractions of the sulfonamides were significantly increased in the serum of obese rats, the influence of which on the volume of distribution and clearance is discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3243323     DOI: 10.1007/BF03190091

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  46 in total

1.  Density of body fat in man and other mammals.

Authors:  F FIDANZA; A KEYS; J T ANDERSON
Journal:  J Appl Physiol       Date:  1953-10       Impact factor: 3.531

2.  Pharmacokinetics of drugs in patients with the nephrotic syndrome.

Authors:  R Gugler; D W Shoeman; D H Huffman; J B Cohlmia; D L Azarnoff
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

3.  Diet and starvation on the composition and calculated density of fat-free body mass.

Authors:  J Mendez; J Kollias
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1977-05

4.  Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man.

Authors:  S A Kaplan; R E Weinfeld; C W Abruzzo; M Lewis
Journal:  J Pharm Sci       Date:  1972-05       Impact factor: 3.534

5.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

6.  Theophylline disposition in obese rats.

Authors:  L Shum; W J Jusko
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

7.  Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate).

Authors:  D R Abernethy; D J Greenblatt; M Divoll; R I Shader
Journal:  J Pharm Sci       Date:  1982-08       Impact factor: 3.534

8.  Fatty liver hepatitis and cirrhosis in obese patients.

Authors:  M Adler; F Schaffner
Journal:  Am J Med       Date:  1979-11       Impact factor: 4.965

Review 9.  Pharmacokinetics of drugs in obesity.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

View more
  2 in total

1.  Quantitative structure--pharmacokinetic relationship of a series of sulfonamides in the rat.

Authors:  S Kaul; W A Ritschel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

2.  Cloning, expression, purification and characterization of human mitochondrial carbonic anhydrase VA.

Authors:  Danish Idrees; Sudhir Kumar; Syed Abdul Arif Rehman; Samudrala Gourinath; Asimul Islam; Faizan Ahmad; Md Imtaiyaz Hassan
Journal:  3 Biotech       Date:  2016-01-07       Impact factor: 2.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.